Other substances

Bromocriptine

An ergot alkaloid.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
8
 AI-suggested references
0
 Clinical trials

General information

Bromocriptine on PubChem

Marketed as

APO-BROMOCRIPTINE; BROMOCRIPTINE; BAGREN; CYCLOSET; ERGOSET; PARLODEL; PRAVIDEL

 

Structure image - Bromocriptine

CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O

Supporting references

Link Tested on Impact factor Notes Publication date
Potential Treatment of Chinese and Western Medicine Targeting Nsp14 of SARS-CoV-2
nsp14 Small molecule In silico 		in silico 2.67

Predicted to bind the SARS-CoV-2 nsp14 protein.

 Sep/07/2020

AI-suggested references

Link Publication date
Targeting COVID-19 in Parkinson's Patients: Drugs Repurposed.
Sep/28/2021
Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.
Mar/16/2021
In silico and in vitro assays reveal potential inhibitors against 3CLpro main protease of SARS-CoV-2.
Sep/22/2021
Drug repositioning against COVID-19: a first line treatment
May/21/2020
Computational screening of FDA approved drugs of fungal origin that may interfere with SARS-CoV-2 spike protein activation, viral RNA replication, and post-translational modification: a multiple target approach.
Apr/04/2021
Potential treatment with Chinese and Western medicine targeting NSP14 of SARS-CoV-2.
Sep/07/2020
Virtual screening, molecular dynamics and structure-activity relationship studies to identify potent approved drugs for Covid-19 treatment
Jul/21/2020
Repurposing of FDA-approved drugs against active site and potential allosteric drug-binding sites of COVID-19 main protease
Jul/05/2021
Export (.csv)